Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 18, 2017
Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Journal: Journal of managed care & specialty pharmacy
Published: July 27, 2016
Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Journal: Expert review of hematology
Published: June 14, 2016
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 28, 2015
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
Journal: American health & drug benefits
Published: April 20, 2015
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.
Journal: Haematologica
Published: November 05, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026